| Andrew Alexander Ke, MD | |
|
1199 Prince Ave, Athens, GA 30606-2797 | |
| (706) 475-5076 | |
| Not Available |
| Full Name | Andrew Alexander Ke |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 9 Years |
| Location | 1199 Prince Ave, Athens, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265826341 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 080926 (Georgia) | Secondary |
| 207R00000X | Internal Medicine | 080926 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Hospital | Athens, GA | Hospital |
| Piedmont Athens Regional Medical Center | Athens, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Athens Hospitalist Services Pc | 6709770167 | 12 |
| Hospital Physician Services - Southeast Professional Corporation | 5597774554 | 640 |
| Piedmont Athens Hospitalist Physicians Llc | 6305196411 | 105 |
| Post-acute Physicians Of Georgia Pc | 4284708751 | 7 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Athens Hospitalist Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295803013 PECOS PAC ID: 6709770167 Enrollment ID: O20040209000626 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Piedmont Hospitalist Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548219660 PECOS PAC ID: 1951299163 Enrollment ID: O20040309000820 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Oconee Valley Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255433736 PECOS PAC ID: 0446232268 Enrollment ID: O20040604000755 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Hospital Physician Services - Southeast Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760410385 PECOS PAC ID: 5597774554 Enrollment ID: O20060419000545 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Post-acute Physicians Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316104698 PECOS PAC ID: 4284708751 Enrollment ID: O20080731000526 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Entity Name | Piedmont Athens Hospitalist Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578079000 PECOS PAC ID: 6305196411 Enrollment ID: O20180911003967 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Alexander Ke, MD 1230 Baxter St, Athens, GA 30606-3712 Ph: (706) 389-3889 | Andrew Alexander Ke, MD 1199 Prince Ave, Athens, GA 30606-2797 Ph: (706) 475-5076 |
News Archive
The World Bank must define life expectancy, its key poverty indicator, as starting at the time of conception and not at the time of birth if millions of lives are to be saved from injury or death. International public health experts, writing in the Journal of the Royal Society of Medicine, said that definitional oversight, in which the life of the child is inadvertently cut into two, ‘inside' and ‘outside' the womb, covers up risks to the fetus and is particularly unfair to children born in areas increasingly at risk to disasters and already disadvantaged by poverty, hunger and social deprivation.
Rice University scientists have discovered a new way to look inside living cells and see the insoluble fibrillar deposits associated with Parkinson's disease.
The president's new birth control plan would insure coverage of women's birth control without copayments or deductibles. Sounds fair, especially given that men's anti-impotence Viagra treatments have been covered by insurance plans for years.
Moderate social drinking significantly reduces the risk of dementia and cognitive impairment, according to an analysis of 143 studies by Loyola University Chicago Stritch School of Medicine researchers.
Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).
› Verified 6 days ago
Bannur Ramanna Nandeesh, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1199 Prince Ave, Athens, GA 30606 Phone: 706-475-5076 | |
Krupal Jay Hari, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 242 King Avenue, Suite 210, Athens, GA 30606 Phone: 706-475-1700 Fax: 706-475-1790 | |
Mr. Ashwin Thatti, Internal Medicine Medicare: Medicare Enrolled Practice Location: 1500 Oglethorpe Ave Ste 500c, Athens, GA 30606 Phone: 706-546-7484 | |
Dr. Stephen William Wilde, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Sunset Dr, Suite 501, Athens, GA 30606 Phone: 706-208-0065 Fax: 706-459-8693 | |
Dr. James S Miller, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1199 Prince Ave, Athens, GA 30606 Phone: 706-475-1700 Fax: 706-546-1787 | |
Dr. Paul Peteet, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Carlton St, Athens, GA 30602 Phone: 706-542-8621 Fax: 706-583-0217 | |
Diana T Blake, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2470 Daniells Bridge Rd Ste 231, Athens, GA 30606 Phone: 706-769-3362 Fax: 706-769-5675 |